We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00726362
First Posted: July 31, 2008
Last Update Posted: December 3, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
July 29, 2008
July 31, 2008
December 3, 2010
December 2007
November 2009   (Final data collection date for primary outcome measure)
Changes on LDL-C, HDL-C, TG, TC [ Time Frame: 3~6 months ]
Same as current
Complete list of historical versions of study NCT00726362 on ClinicalTrials.gov Archive Site
  • ratio for treatment-to-goal [ Time Frame: 3~6 months ]
  • drug compliance [ Time Frame: 3~6 months ]
  • correlation between patient's insight and therapeutic outcome [ Time Frame: 3~6 months ]
Same as current
Not Provided
Not Provided
 
To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia
To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia
The primary objective is to survey the efficacy of various commercially available statins (a class of lipid-lowering agents, for example, rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin and fluvastatin) under local clinical practice in treating patients with hyperlipidemia. Surveillance data (Lipid Profile) will be collected during course of usual clinical practice or captured upon its availability.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
based on regular practice and judged by physicians, patients with hyperlipidemia who need to start prescribed with a statin; or to switch from current therapy to a statin, or require dosage adjustment for statin
Hyperlipidemias
Not Provided
1
patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3270
November 2009
November 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients diagnosed with hyperlipidemia
  • Patients who are just starting a statin treatment, who need to switch from current therapy to a statin medication, or who are receiving dosage adjustment of statin as judged by the physicians
  • Patients who are willing to participate in this study and who sign an informed consent form

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Patient are illiterate or unable to fill the questionnaire for any reason
  • Patients with contraindications to the use of certain statins as needed prescribed by physicians (as per commercially available statins package insert) including the use of rosuvastatin.
  • Any clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT00726362
NIS-CTW-CRE-2007/1
No
Not Provided
Not Provided
William Huang/Medical Director, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Principal Investigator: Wen-Ter Lai, MD Kaohsiung Medical University
AstraZeneca
December 2010